Evidence map›Paper›PMID 41132651›Full record

ArticleFrontiers in immunology2025

Production of functional CD19 CAR T cells under hypoxic manufacturing conditions.

Isabella Micallef Nilsson, Thomas Poiret, Jinhye Ryu, Mohammadali Mohammadpour, Johan Henriksson, Anders Österborg, Jonas Mattsson, Anna Schurich, Isabelle Magalhaes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isabella Micallef NilssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Thomas PoiretDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jinhye RyuDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Mohammadali MohammadpourDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Johan HenrikssonDepartment of Molecular Biology, Umeå Centre for Microbial Research, Umeå University, Umeå, Sweden.
Anders ÖsterborgDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jonas MattssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Anna SchurichDepartment of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Isabelle MagalhaesDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic lymphocytic leukemia (CLL) has proven difficult to treat with chimeric antigen receptor (CAR) T cell therapy. CLL cells can negatively alter T cell fitness and induce a pseudohypoxic state. We hypothesized that production of CAR T cells under restricted oxygen conditions resembling physiological oxygen levels that can be encountered in tissues ( Methods: We performed Results: Production of HD-derived CAR T cells in 2% O Discussion: We demonstrated that production in 2% O

Indexed as

Antigens, CD19Immunotherapy, AdoptiveLeukemia, Lymphocytic, Chronic, B-CellReceptors, Chimeric AntigenT-LymphocytesCell HypoxiaCytokinesHumansLymphocyte ActivationOxygenAntigens, CD19CytokinesOxygenReceptors, Chimeric AntigenCAR T cellsCLL (chronic lymphocytic leukemia)hypoxiamitochondriatumor microenvironment

Identifiers

PMID41132651
PMCPMC12540424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.